✦ LIBER ✦

A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer

✍ Scribed by Maurie Markman

Book ID: 113961905
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 287 KB
Volume: 114
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2008.11.034

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2, randomized, double-blind, pla

A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous Å6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer

✍ Sharad A. Ghamande; Michael H. Silverman; Warner Huh; Kian Behbakht; Greg Ball; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 195 KB

A Phase 2, randomized, double-blind, pla

A Phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer

✍ S.A. Ghamande; M. Silverman; M. Gold 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Efficacy and Safety of Short-Term Genist

Efficacy and Safety of Short-Term Genistein Intervention in Patients with Localized Prostate Cancer Prior to Radical Prostatectomy: A Randomized, Placebo-Controlled, Double-Blind Phase 2 Clinical Trial

✍ Lazarevic, Bato; Boezelijn, Gro; Diep, Lien My; Kvernrod, Kristin; Ogren, Olov; 📂 Article 📅 2011 🏛 Lawrence Erlbaum Associates, Inc. 🌐 English ⚖ 558 KB

A Phase 2b, Double-Blind, Randomized Stu

A Phase 2b, Double-Blind, Randomized Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared With Placebo (PBO) When Administered in Combination With Chemotherapy (Modified FOLFOX6) for First-line Treatment (tx) of Patients (Pts) With Metastatic Colorectal Cancer (mCRC). The RESPECT Trial

✍ J. Tabernero; R. Garcia-Carbonero; C.H. Könne; P.J. O'Dwyer; A. Sobrero; E. Van 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB